Neumora Therapeutics, Inc.

NMRA

US6409791000

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:25:00 2024-05-15 pm EDT			5-day change	1st Jan Change
9.575 ^USD	-0.05%		+2.65%	-43.28%

May. 14	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT
May. 14	Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	CI

Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to S&P Global BMI Index

March 17, 2024

Latest news about Neumora Therapeutics, Inc.

Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	May. 14	MT
Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	May. 14	CI
Neumora Therapeutics Shares Fall as Q1 Loss Narrows	May. 07	MT
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 15	MT
Sector Update: Health Care	Apr. 15	MT
Investors Shrug Off Geopolitical Concerns, Driving Premarket Gains for US Equity Futures	Apr. 15	MT
Upcoming Earnings Buoy Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday	Apr. 15	MT
Top Premarket Decliners	Apr. 15	MT
Neumora Therapeutics' Phase 1 Trial of Potential Brain Disease Drug on Hold After Convulsions in Rabbits	Apr. 15	MT
Neumora Shares Slide Premarket as FDA Puts Early Study of Schizophrenia Drug on Hold	Apr. 15	DJ
Neumora's early-stage schizophrenia drug study put on hold	Apr. 15	RE
U.S. FDA places clinical hold on Neumora's schizophrenia drug study	Apr. 15	RE
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study	Apr. 15	CI
JPMorgan Adjusts Price Target on Neumora Therapeutics to $22 From $20, Maintains Overweight Rating	Mar. 18	MT
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to S&P Global BMI Index	Mar. 17	CI
Certain Common Stock of Neumora Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	Mar. 11	CI
Certain Stock Options of Neumora Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	Mar. 11	CI
RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk	Mar. 08	MT
Neumora Therapeutics Q4 Loss Narrows	Mar. 07	MT
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Neumora Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer	Jan. 22	MT
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer	Jan. 22	CI
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to S&P TMI Index	Dec. 18	CI

Chart Neumora Therapeutics, Inc.

Duration

Period

More charts

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Companyâs therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

Sector

Biotechnology & Medical Research

Calendar

09:00am - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.58 USD

Average target price

24.51 USD

Spread / Average Target

+155.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUMORA THERAPEUTICS, INC.	-43.28%	1.53B
MODERNA, INC.	+29.01%	49.18B
IQVIA HOLDINGS INC.	+0.94%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.44%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.64%	18.71B
BIO-TECHNE CORPORATION	+8.13%	13.26B
MEDPACE HOLDINGS, INC.	+32.17%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.46%	11.99B

Other Biotechnology & Medical Research